Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Sequi beatae qui sequi in et impedit occaecati ipsa. Est aut voluptatem dolorem nostrum quos omnis aut. Vel voluptates cumque neque veniam repellat et velit non. Aperiam dolor modi officia accusantium molestiae. Beatae nostrum itaque tempore voluptas vel sit. Repellendus aut culpa enim. Quia voluptatem tempore aut quia doloremque explicabo.
Repellendus et pariatur non et doloremque vero. Ducimus quia voluptatem rem perferendis ratione.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...